直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Firm
  • Offices
  • Careers
Finnegan
  • Articles & Books
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • IP Health Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
  • Unified Patent Court (UPC) Hub

Podcast

Life Sciences Podcast Series - Inherency and Obviousness

April 29, 2021

By Jill K. MacAlpine, Ph.D.; Alissa K. Lipton; Sara A. Leiman, Ph.D.; Oulu (Lulu) Wang, Ph.D.

The Life Sciences industry can be particularly challenging for companies to navigate, often requiring careful navigation through rigorous testing and regulatory compliance. The Life Sciences Podcasts Series looks at some of the hottest topics in the Life Sciences industry. In this podcast, Finnegan attorneys Jill MacAlpine, Alissa Lipton, Lulu Wang, and Sara Leiman discuss the doctrine of inherency and obviousness and identify notable, recent decisions in the life sciences industry.

Tags

Life Sciences Podcast Series , Obviousness (35 USC § 103), prior art

Downloadable Files

  • Life Sciences Podcast Series - Inherency and Obviousness

Related Practices

Enforcement and Litigation

Related Industries

Life Sciences

Pharmaceutical

Related Offices

Boston, MA

Washington, DC

Related Professionals

Jill_MacAlpine
Jill K. MacAlpine, Ph.D.
Partner
Washington, DC
+1 202 408 4105
Email
Alissa K. Lipton
Partner
Washington, DC
+1 202 408 4293
Email
Sara_Leiman
Sara A. Leiman, Ph.D.
Associate
Boston, MA
+1 617 646 1651
Email

Related Insights

Conference

21st Advanced Summit on Life Sciences Patents

May 18-19, 2023

New York

Workshop

Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology Patent Law

April 27, 2023

Cambridge

Conference

IAM Live: IP and Emerging Technology Europe 2023

April 19, 2023

London

Conference

Microbiome One - Health Conference

March 23-24, 2023

Glasgow

40th FDA Boot Camp

March 22-23, 2023

Virtual

Webinar

Obtaining and Managing REMS Patents: What Patent Prosecutors Need to Know, USPTO and FDA Policies and Rules

March 21, 2023

Webinar

Conference

The National Forum on IP, Funding and Tech Strategies for Novel Therapeutic Modalities and Gene Therapies

March 21-22, 2023

Boston

Federal Circuit IP Blog

Dietary Supplement Patent Invalid Under 35 U.S.C. § 101, Federal Circuit Affirms

March 17, 2023

Prosecution First Blog

ChromaDex Fails to Milk Its Patent for Subject Matter Eligibility

March 17, 2023

Due to international data regulations, we’ve recently updated our privacy policy. Click here to read our privacy policy in full.

We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.

The Finnegan UPC Hub is a one-stop shop for our insights related to the Unified Patent Court (UPC).

Finnegan
Click Here
  • Privacy
  • Disclaimer
  • EEO Statement

© 2023 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP